NEW YORK (GenomeWeb) – The Cancer Research UK Manchester Institute announced today it has joined Cancer-ID, a European consortium to validate blood-based biomarkers for cancer. 

With a total budget of €14.5 million ($15.7 million), Cancer-ID is a newly created consortium funded by the Innovative Medicines Initiative. It currently has 33 members from 13 countries tasked with establishing standard protocols for and clinical validation of blood-based biomarkers, such as circulating tumor cells, cell-free tumor DNA, and microRNAs. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.

Nov
27
Sponsored by
Genialis & Roche

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.